Paliperidone Palmitate Patent Expiration
Paliperidone Palmitate is used for managing symptoms of schizophrenia in patients who have missed doses or need to restart treatment. It was first introduced by Janssen Pharmaceuticals Inc
Paliperidone Palmitate Patents
Given below is the list of patents protecting Paliperidone Palmitate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Invega Hafyera | US11666697 | Methods for ensuring resuspension of paliperidone palmitate formulations | Nov 24, 2041 | Janssen Pharms |
| Invega Hafyera | US11304951 | Dosing regimens associated with extended release paliperidone injectable formulations | May 07, 2041 | Janssen Pharms |
| Invega Hafyera | US11324751 | Dosing regimens associated with extended release paliperidone injectable formulations | May 07, 2041 | Janssen Pharms |
| Invega Hafyera | US12208100 | Dosing regimens associated with extended release paliperidone injectable formulations | May 07, 2041 | Janssen Pharms |
| Erzofri | US11666573 | Dosage regimen of paliperidone palmitate extended-release injectable suspension | Sep 24, 2039 | Luye Innomind Pharma |
| Erzofri | US12128049 | Dosage regimen of paliperidone palmitate extended-release injectable suspension | Oct 26, 2038 | Luye Innomind Pharma |
| Invega Trinza | US10143693 | Dosing regimen for missed doses for long-acting injectable paliperidone esters | Apr 05, 2036 | Janssen Pharms |
| Invega Sustenna | US9439906 | Dosing regimen associated with long acting injectable paliperidone esters | Jan 26, 2031 | Janssen Pharms |
| Invega Sustenna |
US6555544 (Pediatric) | Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters |
May 10, 2019
(Expired) | Janssen Pharms |
| Invega Sustenna | US6555544 | Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters |
Nov 10, 2018
(Expired) | Janssen Pharms |
| Invega Sustenna |
US6077843 (Pediatric) | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
Nov 12, 2017
(Expired) | Janssen Pharms |
| Invega Trinza |
US6077843 (Pediatric) | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
Nov 12, 2017
(Expired) | Janssen Pharms |
| Invega Sustenna | US6077843 | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
May 12, 2017
(Expired) | Janssen Pharms |
| Invega Trinza | US6077843 | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
May 12, 2017
(Expired) | Janssen Pharms |
| Invega Sustenna |
US5254556 (Pediatric) | 3-piperidinyl-1,2-benzisoxazoles |
Apr 15, 2014
(Expired) | Janssen Pharms |
| Invega Sustenna | US5254556 | 3-piperidinyl-1,2-benzisoxazoles |
Oct 15, 2013
(Expired) | Janssen Pharms |
| Invega Sustenna |
US5352459 (Pediatric) | Use of purified surface modifiers to prevent particle aggregation during sterilization |
Jun 16, 2013
(Expired) | Janssen Pharms |
| Invega Sustenna | US5352459 | Use of purified surface modifiers to prevent particle aggregation during sterilization |
Dec 16, 2012
(Expired) | Janssen Pharms |
Paliperidone Palmitate's Family Patents
Explore Our Curated Drug Screens
Paliperidone Palmitate Generic API Manufacturers
Several generic applications have been filed for Paliperidone Palmitate.
Given below is the list of companies who have filed for Paliperidone Palmitate generic, along with the locations of their manufacturing plants worldwide.
1. TEVA PHARMS USA
Teva Pharmaceuticals Usa Inc has filed for 5 different strengths of generic version for Paliperidone Palmitate. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 39MG/0.25ML (39MG/0.25ML) | suspension, extended release | Prescription | INTRAMUSCULAR | AB | Jul 6, 2021 |
| 78MG/0.5ML (78MG/0.5ML) | suspension, extended release | Prescription | INTRAMUSCULAR | AB | Jul 6, 2021 |
| 117MG/0.75ML (117MG/0.75ML) | suspension, extended release | Prescription | INTRAMUSCULAR | AB | Jul 6, 2021 |
| 156MG/ML (156MG/ML) | suspension, extended release | Prescription | INTRAMUSCULAR | AB | Jul 6, 2021 |
| 234MG/1.5ML (156MG/ML) | suspension, extended release | Prescription | INTRAMUSCULAR | AB | Jul 6, 2021 |